MedTrace Logo

Short Course Radical Cure of P. Vivax Malaria in Nepal

NCT04079621 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2024-08-29

No results posted yet for this study

Summary

This study is designed as a multicentre randomized, open label trial to assess the safety and efficacy of a low dose short course PQ treatment (3.5mg/kg total dose given over 7 days) in glucose-6-phosphate dehydrogenase (G6PD) normal patients with P.vivax and P falciparum to reduce the risk of subsequent P.vivax episodes.

Conditions

  • Malaria
  • Malaria, Vivax
  • Malaria,Falciparum

Interventions

DRUG

primaquine

Primaquine regimen over 7 days (0.5mg/kg/day for 7 days)

Sponsors & Collaborators

  • Tribhuvan University, Nepal

    collaborator OTHER

  • Menzies School of Health Research

    lead OTHER

Principal Investigators

  • Kamala Ley-Thriemer, MD, PhD · Menzies School of Health Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-27
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • Nepal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04079621 on ClinicalTrials.gov